TUBB3 (βIII-tubulin) drives gastric cancer progression and poor prognosis by regulating cell cycle and invadopodia formation

Cancer Biomarkers · Published 2025-10-01 · DOI 10.1177/18758592251390145

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1177/18758592251390145

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• A causal association between Epstein-Barr virus infection and lung cancer: A two-sample Mendelian Randomization study · Cancer Biomarkers · 2026 · Same journal
• Serum exosomal miR-1275 as a potential biomarker for the diagnosis and prognostic assessment of hepatocellular carcinoma · Cancer Biomarkers · 2025 · Same journal
• Multi-cancer early detection tests: Attributes for clinical implementation · Cancer Biomarkers · 2025 · Same journal
• Systematic exploration of prognostic alternative splicing events related to tumor immune microenvironment of Clear Cell Renal Cell Carcinoma · Cancer Biomarkers · 2025 · Same journal
• Panax notoginseng improves the sensitivity of non-small cell lung cancer to cisplatin by inhibiting Akt signaling · Cancer Biomarkers · 2025 · Same journal
• Role of immune cell subsets in liver fibrosis through single-cell RNA sequencing and array · Cancer Biomarkers · 2025 · Same journal
• Identifying diagnostic markers and establishing prognostic model for lung cancer based on lung cancer-derived exosomal genes · Cancer Biomarkers · 2025 · Same journal
• The effect of low-intensity resistance exercise training on Serum tumor biomarkers and quality of life in women with breast cancer: A randomized controlled trial · Cancer Biomarkers · 2025 · Same journal
• The overexpression of HOXC6 in LUSC and pan-squamous cell carcinomas indicates the coexistence of nuclear division regulatory mechanisms · Cancer Biomarkers · 2025 · Same journal
• Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma · Cancer Biomarkers · 2025 · Same journal